Clinical studies demonstrated strong activity of the BTK inhibitor ibrutinib and the mTOR inhibitor temsirolimus in subsets of MCL (23, 37), and our finding reveals potential biomarkers for treatment. The gene discussed is BTK; the disease is mantle cell lymphoma.